Loading
A phase 3 trial of Trastuzumab rezetecan and Trastuzumab emtansine in HER2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy is a phase 3 interventional study registered as NCT06126640 by Jiangsu HengRui Medicine Co., Ltd., with 1615 participants enrolled, started 2023-11-20 and due to reach its primary completion in 2030-04. Interventions recorded: SHR-A1811 and Trastuzumab Emtansine.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab emtansine, Early HER2-positive breast cancer, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.